The Flow Cytometry Core at MSKCC provides researchers at MSKCC with state of the art flow cytometry services, including cell sorting. These services include operator-assisted flow cytometry analysis on a CyAn and a FACSCaliburflow cytometer, self-operated flow analysis on two 5-color (upgraded) FACScans and a FACSCalibur, and operator-assisted cell sorting on one 4-laser MoFlo, one 3-laser MoFlo, and one 3-laser DiVa cell sorter. Extensive training in flow cytometry is offered, and a site license for Flowjo is administered by the core facility. An additional cell purification option, Miltenyi AutoMACS, is made available to all users. The availability of these services enables the researchers at MSKCC to isolate and characterize specific cellular subsets, and to analyze the effects of manipulations aimed at answering a multitude of scientific questions that arise within the context of cancer research. The core facility's services play in important role in enabling the researchers to ask specific questions regarding ever smaller subsets of cells, down to the single cell level. Many of these questions can only be answered when purified fractions of specific cell subsets can be identified and isolated, which is the domain of flow analysis and cell sorting.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-47
Application #
8375223
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2013-12-31
Budget Start
2012-01-09
Budget End
2012-12-31
Support Year
47
Fiscal Year
2012
Total Cost
$190,645
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Antonescu, Cristina R; Agaram, Narasimhan P; Sung, Yun-Shao et al. (2018) A Distinct Malignant Epithelioid Neoplasm With GLI1 Gene Rearrangements, Frequent S100 Protein Expression, and Metastatic Potential: Expanding the Spectrum of Pathologic Entities With ACTB/MALAT1/PTCH1-GLI1 Fusions. Am J Surg Pathol 42:553-560
Baumann, Michael H; Majumdar, Susruta; Le Rouzic, Valerie et al. (2018) Pharmacological characterization of novel synthetic opioids (NSO) found in the recreational drug marketplace. Neuropharmacology 134:101-107
Escalon, Joanna G; Harrington, Kate A; Plodkowski, Andrew J et al. (2018) Malignant Pleural Mesothelioma: Are There Imaging Characteristics Associated With Different Histologic Subtypes on Computed Tomography? J Comput Assist Tomogr 42:601-606
Rosen, Lauren E; Karrison, Theodore; Ananthanarayanan, Vijayalakshmi et al. (2018) Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. Mod Pathol 31:598-606
Argani, Pedram; Pawel, Bruce; Szabo, Sara et al. (2018) Diffuse Strong BCOR Immunoreactivity Is a Sensitive and Specific Marker for Clear Cell Sarcoma of the Kidney (CCSK) in Pediatric Renal Neoplasia. Am J Surg Pathol 42:1128-1131
Lambertini, Matteo; Campbell, Christine; Bines, José et al. (2018) Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients. J Natl Cancer Inst :
Intlekofer, Andrew M; Joffe, Erel; Batlevi, Connie L et al. (2018) Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay. Blood Cancer J 8:60
Wang, Hongmei; Deng, Jikui; Tang, Yi-Wei (2018) Profile of the Alere i Influenza A & B assay: a pioneering molecular point-of-care test. Expert Rev Mol Diagn 18:403-409
Tseng, Jill H; Aloisi, Alessia; Sonoda, Yukio et al. (2018) Long-Term Oncologic Outcomes of Uterine-Preserving Surgery in Young Women With Stage Ib1 Cervical Cancer. Int J Gynecol Cancer 28:1350-1359
Pronier, Elodie; Bowman, Robert L; Ahn, Jihae et al. (2018) Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood 132:1265-1278

Showing the most recent 10 out of 8799 publications